

Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

None

None

L10I ^{100%}_{cons=28,795} • I13V ^{100%}_{cons=29,525} • L19I ^{99%}_{cons=25,183} • E35D ^{100%}_{cons=28,863} • M36I ^{99%}_{cons=28,838} • N37D ^{99%}_{cons=28,863} • R41K ^{99%}_{cons=27,582} • H69K ^{99%}_{cons=22,758} • L89M ^{100%}_{cons=32,879}

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

L10I/V

are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None	
NNRTI Mutations:	None	
RT Other Mutations:	V21I ^{99%} _{cons=7,776} • K32KE ^{R: 10%, D: 20%} _{cons=15,676} • V35T ^{100%} _{cons=3,267} • T39L ^{92%} _{cons=2,257} • V60I ^{100%} _{cons=1,870} • D121H ^{99%} _{cons=562} • K122E ^{99%} _{cons=562} • I135R ^{98%} _{cons=1,217} • K173S ^{99%} _{cons=2,329} • Q174K ^{97%} _{cons=2,329} • D177E ^{99%} _{cons=2,326} • G196E ^{99%} _{cons=1,523} • I202V ^{R: 40%, D: 20%} _{cons=2,265} • Q207A ^{99%} _{cons=870} • R211S ^{99%} _{cons=859} • V245Q ^{99%} _{cons=83} • D250E ^{100%} _{cons=58} • A272P ^{100%} _{cons=76} • K512KR ^{R: 40%, D: 20%} _{cons=2,554} • S519N ^{100%} _{cons=3,589} • Q524K ^{99%} _{cons=6,290} • K527G ^{99%} _{cons=3,554} • E529D ^{97%} _{cons=3,864} • A534S ^{99%} _{cons=4,525} • A554S ^{99%} _{cons=15,282} • K558KR ^{R: 50%, D: 20%} _{cons=8,753}	
Nucleoside Reverse Transcriptase Inhibitors		
abacavir (ABC)	Susceptible	
zidovudine (AZT)	Susceptible	
stavudine (D4T)	Susceptible	
didanosine (DDI)	Susceptible	
emtricitabine (FTC)	Susceptible	
lamivudine (3TC)	Susceptible	
tenofovir (TDF)	Susceptible	
Non-nucleoside Reverse Transcriptase Inhibitors		
doravirine (DOR)	Susceptible	
efavirenz (EFV)	Susceptible	
etravirine (ETR)	Susceptible	
nevirapine (NVP)	Susceptible	
rilpivirine (RPV)	Susceptible	

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

INSTI Major Mutations:	None
INSTI Accessory Mutations:	None
IN Other Mutations:	K14R 99% cons=4,352 • V31I 100% cons=8,358 • I72V 100% cons=3,867 • T112V 100% cons=8,223 • I113V 100% cons=8,223 • T124A 100% cons=3,758 • T125A 100% cons=3,756 • K136Q 100% cons=3,546 • V201I 99% cons=6,202 • Y227F 100% cons=5,596 • S230N 99% cons=3,523 • L234V 100% cons=5,596 • S255SN 5-82%, N 10% cons=8,751 • D256E 100% cons=3,563 • A265V 99% cons=8,781 • S283G 100% cons=8,360
<hr/> Integrase Strand Transfer Inhibitors <hr/>	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments	
Other	
• S230N is a polymorphism that is not associated with reduced INSTI susceptibility.	

Mutation scoring: IN	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for INSTI.